CMP
CRSP icon

Coston McIsaac & Partners’s CRISPR Therapeutics CRSP Stock Holding History

Coston McIsaac & Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25
Closed -$1K – 774
2023
Q1 		$1K Hold
25
– – ﹤0.01% 747
2022
Q4 		$1 Hold
25
– – ﹤0.01% 718
2022
Q3 		$1K Hold
25
– – ﹤0.01% 636
2022
Q2 		$2K Buy
+25
New +$1.47K ﹤0.01% 417

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Coston McIsaac & Partners's CRSP Position: Q2 2023 in Review

Coston McIsaac & Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 25 shares — an estimated $1K sold.

Coston McIsaac & Partners first reported a position in CRSP in Q2 2022 and held it in 4 quarters. The position peaked at $2K in Q2 2022. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

  • Coston McIsaac & Partners reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Coston McIsaac & Partners sold 25 CRISPR Therapeutics shares in Q2 2023, an estimated $1K.
  • Coston McIsaac & Partners first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 4 quarters.
  • Coston McIsaac & Partners's CRISPR Therapeutics position peaked at $2K in Q2 2022.
  • 418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Coston McIsaac & Partners's 13F filing for Q2 2023, filed 1 Aug 2023.